Advyzon Investment Management LLC Invests $215,000 in Zoetis Inc. $ZTS

Advyzon Investment Management LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,380 shares of the company’s stock, valued at approximately $215,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Brighton Jones LLC increased its stake in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares in the last quarter. CWM LLC boosted its stake in shares of Zoetis by 23.7% in the first quarter. CWM LLC now owns 22,367 shares of the company’s stock worth $3,683,000 after acquiring an additional 4,282 shares during the last quarter. Whittier Trust Co. increased its position in shares of Zoetis by 2.2% during the first quarter. Whittier Trust Co. now owns 12,437 shares of the company’s stock worth $2,048,000 after purchasing an additional 270 shares in the last quarter. Wealthfront Advisers LLC raised its stake in Zoetis by 24.7% in the 1st quarter. Wealthfront Advisers LLC now owns 24,213 shares of the company’s stock valued at $3,987,000 after purchasing an additional 4,790 shares during the last quarter. Finally, Larson Financial Group LLC lifted its stake in shares of Zoetis by 19.7% in the first quarter. Larson Financial Group LLC now owns 1,556 shares of the company’s stock worth $256,000 after buying an additional 256 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $121.30 on Thursday. The stock’s 50-day simple moving average is $142.21 and its 200-day simple moving average is $151.94. The firm has a market capitalization of $53.45 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $117.26 and a fifty-two week high of $181.85. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Morgan Stanley lowered their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $180.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.